Press Releases

Date Title and Summary Additional Formats
Toggle Summary Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products
Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75 million upfront payment, up to $100 million in research support, a co-commercialization option, and potential future opt-in fees, milestones and royalties
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David Johnston , chief financial officer, will present at the upcoming Canaccord Genuity Growth Conference .
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results
Data Presented at ASCO Support Broad Potential of Mirvetuximab Soravtansine in Ovarian Cancer Sanofi and Debiopharm Transactions Strengthen Cash Position Conference Call to be Held at 8:00am ET Today WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc .
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 28, 2017 , to discuss its second quarter
View HTML
Toggle Summary ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia
Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities Dose-dependent biological and anti-leukemia activity observed WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
View HTML
Toggle Summary ImmunoGen and Sanofi Amend License Agreements
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , president and chief executive officer, will present at the upcoming Jefferies 2017 Global Healthcare
View HTML
Toggle Summary Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting
Pooled analyses of Phase 1 expansion cohorts demonstrate clinically meaningful activity in patient population being studied in FORWARD I registration trial Top-line data from FORWARD II indicate favorable safety and efficacy profile in multiple combinations Conference call scheduled for 8:00am ET
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Activated in North America and Europe Data at AACR and SGO Annual Meetings Highlight Patient Selection Strategy for FORWARD I and Breadth of ADC Expertise Mirvetuximab Soravtansine Safety and Efficacy Data to be Presented at ASCO Annual Meeting
View HTML